ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

PREMPRO 0.625mg/5mg
Menopause and HRT
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

PREMPRO 0.625mg/5mg Rx

Generic Name and Formulations:
Conjugated estrogens 0.625mg, medroxyprogesterone acetate 5mg; tabs.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for PREMPRO 0.625mg/5mg:

In women with an intact uterus: moderate to severe vasomotor symptoms due to menopause; moderate to severe vulvar and vaginal atrophy due to menopause; postmenopausal osteoporosis prevention (consider alternative treatments).

Adult:

1 tab once daily.

Children:

Not applicable.

Contraindications:

Known, suspected, or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Pulmonary embolism/DVT (active or history of). Arterial thromboembolism (eg, stroke, MI; active or history of). Protein C, protein S, or antithrombin deficiency, or other known thromboembolic disorders. Liver dysfunction or disease. Known or suspected pregnancy (Cat.X).

Warnings/Precautions:

Not for prevention of cardiovascular disease. Use for shortest duration consistent with treatment goals and risks. Reevaluate periodically. Gallbladder disease. Hypercalcemia in breast cancer or bone metastases. Conditions aggravated by fluid retention. Familial hyperlipidemia. Hypercoagulation states. Hereditary angioedema. Do initial complete physical and repeat at least yearly (include BP, PAP smear, mammogram). Discontinue if cardiovascular events or visual abnormalities occur or are suspected; if jaundice occurs; and during immobilization for at least 4–6 weeks before surgery associated with thromboembolism. May interfere with lab tests; see literature. Nursing mothers: not recommended.

See Also:

PREMPRO 0.3mg/1.5mg

PREMPRO 0.45mg/1.5mg

PREMPRO 0.625mg/2.5mg

Pharmacological Class:

Estrogen + progestin.

Adverse Reactions:

See literature. Increased risk of cardiovascular events, breast cancer (in prolonged use). GI upset, pain, cramps, hepatic impairment, mastodynia, breakthrough bleeding, altered cervical secretion, vaginal infections, edema, worsening of porphyria, headache, migraine, dizziness, dementia, changes in vision, intolerance to contact lenses, hair loss, weight or libido changes, anaphylactic reactions, angioedema.

How Supplied:

Blister card (28 tabs)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs